N/A N=347 Use of an Occlusal Support Device During the Second Stage of Labor
Pregnancy
Primary: Stage 2 Duration of Labor — 120.2; 107 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=344 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
Non-segmental Vitiligo
Primary: Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 — 30.9; 11.4 percentage of…
Phase 2 N=40 Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Breast Cancer
Primary: Number of Participants That Achieved Pathologic Complete Response (CR) — 11 Participants
Phase 3 N=21 Vaginal Estriol in Multiple Sclerosis
Multiple Sclerosis · Neurogenic Bladder
Primary: Change in Bladder Control Scale (BLCS) — -9 score on a scale — p=0.002
N/A N=38 Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: 1-hour Pad Weight Test — -9.0; -6.3; -4.4 Grams
Phase 4 N=100 Serratus Plane Versus Paravertebral Nerve Blocks for Breast Surgery
Breast Surgery
Primary: Mean/Median Numeric Rating Scale Pain Score Within the Recovery Room — 4; 0 score on a scale — p=0.001
Phase 2 N=6 Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma · Head and Neck Cancer
Primary: Toxicity Rate — 20 Number of adverse events
Phase 3 N=751 The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
Major Depressive Disorder
Primary: Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score — -13.4; -13.8; -14.8 score on a scale — p=0.6798
Phase 3 N=734 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
Spondyloarthritis
Primary: Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14 — 18.2; 44.5 percentage of…
Phase 2 N=19 Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
Adult Lymphoblastic Lymphoma
Primary: Percentage of Subjects Disease-free Survival — 63.2 percentage of participants
N/A N=43 Pilot of Lifestyle and Asthma Intervention
Asthma
Primary: Weight Loss — 43 Participants — p=.35
Phase 2 N=12 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
Sarcoma
Primary: Phase I: Recommended Phase II Dose of Vorinostat — 300 mg/day of Vorinostat
N/A N=23 Optical Imaging Measurement of Intravascular Solution Efficacy Trial
Peripheral Artery Disease
Primary: Quality of Images — .702; .872; .10; .743 Clear imaging field (CIF) proportion
Phase 3 N=330 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
Non-segmental Vitiligo
Primary: Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24 — 29.8; 7.4 percentage of…
N/A N=153 Evaluation of the Use of EZCare/V1STA in the Management of Acute and Chronic Wounds
Wounds
Primary: Number of Wounds Stratified by Wound Area for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With…